Literature DB >> 28006972

Identifying HIV care enrollees at-risk for cannabis use disorder.

Bryan Hartzler1, Beatriz H Carlini1, Howard Newville1, Heidi M Crane2, Joseph J Eron3,4, Elvin H Geng5, W Christopher Mathews6, Kenneth H Mayer7,8,9, Richard D Moore10,11,12, Michael J Mugavero13, Sonia Napravnik3, Benigno Rodriguez14, Dennis M Donovan1,15.   

Abstract

Increased scientific attention given to cannabis in the United States has particular relevance for its domestic HIV care population, given that evidence exists for both cannabis as a therapeutic agent and cannabis use disorder (CUD) as a barrier to antiretroviral medication adherence. It is critical to identify relative risk for CUD among demographic subgroups of HIV patients, as this will inform detection and intervention efforts. A Center For AIDS Research Network of Integrated Clinical Systems cohort (N = 10,652) of HIV-positive adults linked to care at seven United State sites was examined for this purpose. Based on a patient-report instrument with validated diagnostic threshold for CUD, the prevalence of recent cannabis use and corresponding conditional probabilities for CUD were calculated for the aggregate sample and demographic subgroups. Generalized estimating equations then tested models directly examining patient demographic indices as predictors of CUD, while controlling for history and geography. Conditional probability of CUD among cannabis-using patients was 49%, with the highest conditional probabilities among demographic subgroups of young adults and those with non-specified sexual orientation (67-69%) and the lowest conditional probability among females and those 50+ years of age (42% apiece). Similarly, youthful age and male gender emerged as robust multivariate model predictors of CUD. In the context of increasingly lenient policies for use of cannabis as a therapeutic agent for chronic conditions like HIV/AIDS, current study findings offer needed direction in terms of specifying targeted patient groups in HIV care on whom resources for enhanced surveillance and intervention efforts will be most impactful.

Entities:  

Keywords:  Cannabis use disorder; HIV/AIDS; United States; care settings

Mesh:

Year:  2016        PMID: 28006972      PMCID: PMC5573588          DOI: 10.1080/09540121.2016.1271393

Source DB:  PubMed          Journal:  AIDS Care        ISSN: 0954-0121


  22 in total

1.  Initial treatment of HIV infection: randomized trials with clinical end points are still needed.

Authors:  Michael D Hughes
Journal:  J Infect Dis       Date:  2006-07-31       Impact factor: 5.226

2.  To GEE or not to GEE: comparing population average and mixed models for estimating the associations between neighborhood risk factors and health.

Authors:  Alan E Hubbard; Jennifer Ahern; Nancy L Fleischer; Mark Van der Laan; Sheri A Lippman; Nicholas Jewell; Tim Bruckner; William A Satariano
Journal:  Epidemiology       Date:  2010-07       Impact factor: 4.822

3.  Prevalence and Predictors of Substance Use Disorders Among HIV Care Enrollees in the United States.

Authors:  Bryan Hartzler; Julia C Dombrowski; Heidi M Crane; Joseph J Eron; Elvin H Geng; W Christopher Mathews; Kenneth H Mayer; Richard D Moore; Michael J Mugavero; Sonia Napravnik; Benigno Rodriguez; Dennis M Donovan
Journal:  AIDS Behav       Date:  2017-04

4.  Sexual orientation disparities in psychiatric and drug use disorders among a nationally representative sample of women with alcohol use disorders.

Authors:  Ethan H Mereish; Ji Hyun Lee; Kristi E Gamarel; Nickolas D Zaller; Don Operario
Journal:  Addict Behav       Date:  2015-03-31       Impact factor: 3.913

5.  Pain, Cannabis Species, and Cannabis Use Disorders.

Authors:  Nicole L Cohen; Adrienne J Heinz; Mark Ilgen; Marcel O Bonn-Miller
Journal:  J Stud Alcohol Drugs       Date:  2016-05       Impact factor: 2.582

6.  Drinking trajectories among HIV-infected men who have sex with men: a cohort study of United States veterans.

Authors:  Brandon D L Marshall; Don Operario; Kendall J Bryant; Robert L Cook; E Jennifer Edelman; Julie R Gaither; Adam J Gordon; Christopher W Kahler; Stephen A Maisto; Kathleen A McGinnis; Jacob J van den Berg; Nickolas D Zaller; Amy C Justice; David A Fiellin
Journal:  Drug Alcohol Depend       Date:  2015-01-02       Impact factor: 4.492

7.  Marijuana use and its association with adherence to antiretroviral therapy among HIV-infected persons with moderate to severe nausea.

Authors:  Bouke C de Jong; Diane Prentiss; Willi McFarland; Rhoderick Machekano; Dennis M Israelski
Journal:  J Acquir Immune Defic Syndr       Date:  2005-01-01       Impact factor: 3.731

8.  Poverty matters: contextualizing the syndemic condition of psychological factors and newly diagnosed HIV infection in the United States.

Authors:  Catherine E Oldenburg; Amaya G Perez-Brumer; Sari L Reisner
Journal:  AIDS       Date:  2014-11-28       Impact factor: 4.177

9.  Words Can Be Deceiving: A Review of Variation Among Legally Effective Medical Marijuana Laws in the United States.

Authors:  Rosalie Liccardo Pacula; Priscillia Hunt; Anne Boustead
Journal:  J Drug Policy Anal       Date:  2014-12

10.  Substance use among HIV-infected patients engaged in primary care in the United States: findings from the Centers for AIDS Research Network of Integrated Clinical Systems cohort.

Authors:  Matthew J Mimiaga; Sari L Reisner; Chris Grasso; Heidi M Crane; Steven A Safren; Mari M Kitahata; Joseph E Schumacher; W Christopher Mathews; Kenneth H Mayer
Journal:  Am J Public Health       Date:  2013-06-13       Impact factor: 9.308

View more
  9 in total

1.  A Comparison of Motivations for Marijuana Use in HIV-Positive and HIV-Negative Adults.

Authors:  Sheri L Towe; Olivia E Horton; Bianca Martin; Christina S Meade
Journal:  AIDS Behav       Date:  2018-09

Review 2.  Reciprocal Influences of HIV and Cannabinoids on the Brain and Cognitive Function.

Authors:  Sheri L Towe; Christina S Meade; Christine C Cloak; Ryan P Bell; Julian Baptiste; Linda Chang
Journal:  J Neuroimmune Pharmacol       Date:  2020-05-22       Impact factor: 4.147

3.  A Mapping Literature Review of Medical Cannabis Clinical Outcomes and Quality of Evidence in Approved Conditions in the USA from 2016 to 2019.

Authors:  Sebastian Jugl; Aimalohi Okpeku; Brianna Costales; Earl J Morris; Golnoosh Alipour-Haris; Juan M Hincapie-Castillo; Nichole E Stetten; Ruba Sajdeya; Shailina Keshwani; Verlin Joseph; Yahan Zhang; Yun Shen; Lauren Adkins; Almut G Winterstein; Amie Goodin
Journal:  Med Cannabis Cannabinoids       Date:  2021-02-25

4.  Synergistic effects of HIV and marijuana use on functional brain network organization.

Authors:  Shana A Hall; Zahra Lalee; Ryan P Bell; Sheri L Towe; Christina S Meade
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2020-07-18       Impact factor: 5.067

5.  Change in marijuana use and its associated factors among persons living with HIV (PLWH) during the COVID-19 pandemic: Findings from a prospective cohort.

Authors:  Yan Wang; Gladys E Ibañez; Krishna Vaddiparti; Nichole E Stetten; Ruba Sajdeya; Eric C Porges; Ronald A Cohen; Robert L Cook
Journal:  Drug Alcohol Depend       Date:  2021-05-21       Impact factor: 4.852

6.  HIV Tat Protein Selectively Impairs CB1 Receptor-Mediated Presynaptic Inhibition at Excitatory But Not Inhibitory Synapses.

Authors:  Mariah M Wu; Stanley A Thayer
Journal:  eNeuro       Date:  2020-06-19

7.  HCV cure: an appropriate moment to reduce cannabis use in people living with HIV? (ANRS CO13 HEPAVIH data).

Authors:  Tangui Barré; Patrick Mercié; Caroline Lions; Patrick Miailhes; David Zucman; Hugues Aumaître; Laure Esterle; Philippe Sogni; Patrizia Carrieri; Dominique Salmon-Céron; Fabienne Marcellin
Journal:  AIDS Res Ther       Date:  2022-03-15       Impact factor: 2.250

8.  Medical conditions of primary care patients with documented cannabis use and cannabis use disorder in electronic health records: a case control study from an academic health system in a medical marijuana state.

Authors:  Howard Padwa; David Huang; Larissa Mooney; Christine E Grella; Darren Urada; Douglas S Bell; Brittany Bass; Anne E Boustead
Journal:  Subst Abuse Treat Prev Policy       Date:  2022-05-08

Review 9.  Confound, Cause, or Cure: The Effect of Cannabinoids on HIV-Associated Neurological Sequelae.

Authors:  Alexander Starr; Kelly L Jordan-Sciutto; Eugene Mironets
Journal:  Viruses       Date:  2021-06-26       Impact factor: 5.048

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.